证券代码：300288 证券简称：朗玛信息 公告编号：2025-019 贵阳朗玛信息技术股份有限公司 2024年年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 贵阳朗玛信息技术股份有限公司（以下简称"公司"、"本公司"）2024 年年度权益分派方案已获2025年5月16日召开的2024年年度股东大会审议通过， 现将权益分派事宜公告如下： 一、股东大会审议通过利润分配预案情况 1、公司于2025年5月16日召开2024年年度股东大会，审议通过了《关于2024 年度利润分配预案的议案》，公司2024年度的利润分配预案为：以2024年12月 31日公司总股本337,941,402股为基数，向全体股东每10股派发现金0.15元（含 税），合计派发现金股利5,069,121.03元（含税），不送红股，不以公积金转 增股本，实施上述分配后，剩余未分配利润结转以后年度。若在分配预案实施 前公司总股本发生变动的，按照分配总额不变的原则对分配比例进行相应调整。 2、自利润分配预案披露至实施期间，公司股本总额未发生变化。 3、本次实施的权益分派方案与公司20 ...

Group 1 - The core business of the company includes "medical services + internet medical services" and "telecommunications and value-added telecommunications services" [1] - The company's main products are IPTV services, telephone services, mobile resale services, and medical information services [1] - As of May 29, the company's stock closed at 14.37 yuan, up 3.31%, with a latest price-to-book ratio of 4.47 and a total market value of 4.856 billion yuan [1] Group 2 - In the latest quarterly report for Q1 2025, the company achieved operating revenue of 72.9867 million yuan, a year-on-year decrease of 8.15%, and a net profit of 6.4954 million yuan, a year-on-year increase of 2.77% [1] - The company's gross profit margin stands at 35.11% [1] - The company experienced a net outflow of 2.1812 million yuan in principal funds on May 29, but overall, there was a net inflow of 19.2897 million yuan over the past five days [1]

Core Viewpoint - Langma Information's recent performance shows a decline in revenue while maintaining a slight increase in net profit, indicating potential challenges in the market despite a stable gross margin [1] Group 1: Company Overview - Langma Information Technology Co., Ltd. operates in two main business segments: "medical services + internet medical services" and "telecommunications and value-added telecommunications services" [1] - The company's primary products include IPTV services, telephone services, mobile resale services, and medical information services [1] Group 2: Financial Performance - For Q1 2025, Langma Information reported revenue of 72.99 million yuan, a year-on-year decrease of 8.15% [1] - The net profit for the same period was 6.50 million yuan, reflecting a year-on-year increase of 2.77% [1] - The sales gross margin stood at 35.11% [1] Group 3: Market Position - As of the latest data, Langma Information's closing stock price was 14.21 yuan, with a market capitalization of 4.802 billion yuan and a price-to-book ratio of 4.42 [1] - The company is currently held by four institutions, with a total holding of 15.57 million shares valued at 233 million yuan [1] Group 4: Comparative Analysis - Langma Information's PE (TTM) is -9.38, while the industry average PE is 74.38, indicating a significant disparity in valuation metrics [2] - The industry median PE is 81.13, further highlighting Langma Information's underperformance relative to its peers [2]

证券代码：300288 证券简称：朗玛信息 公告编号：2025-018 贵阳朗玛信息技术股份有限公司 2024年年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、贵阳朗玛信息技术股份有限公司于2025年4月25日在中国证监会指定信息 披露网站巨潮资讯网上披露了《关于召开2024年年度股东大会的通知公告》； 2、本次股东大会无增加、变更、否决提案的情况； 3、本次股东大会未涉及变更前次股东大会决议的情形； 4、本次股东大会采取现场投票与网络投票相结合的表决方式。 一、会议召开和出席情况 （一）会议召开情况 1、召开会议时间： （1）现场会议召开时间：2025 年 5 月 16 日（星期五）15:00。 ① 深圳证券交易所交易系统投票的时间：2025 年 5 月 16 日 9:15—9:25， 9:30—11:30 和 13:00—15:00； ② 深圳证券交易所互联网系统投票的时间：2025 年 5 月 16 日 9:15 至 15:00 的任意时间。 2、现场会议召开地点：贵州省贵阳市国家高新技术产业开发区金阳科技产 业园长 ...

广东省深圳市福田区中心四路 1-1 号 嘉里建设广场第三座第 28 层 2803-04 室 邮编：518048 电话：（86-755）2939-5288 传真：（86-755）2939-5289 北京市君合（深圳）律师事务所 关于贵阳朗玛信息技术股份有限公司 2024 年年度股东大会的法律意见书 致：贵阳朗玛信息技术股份有限公司 受贵公司的委托，北京市君合（深圳）律师事务所（以下简称"本所"）根据 《中华人民共和国公司法》（以下简称《公司法》）、《上市公司股东会规则》(以下简 称《股东会规则》）等法律、法规、规章及《贵阳朗玛信息技术股份有限公司章程》 （以下简称《公司章程》）的有关规定，就贵公司 2024 年年度股东大会（以下简称 "本次股东大会"）的有关事宜，出具本法律意见。 本法律意见书仅就本次股东大会的召集和召开程序、出席本次股东大会人员的 资格、召集人资格、会议表决程序是否符合中国相关法律、法规及《公司章程》的 规定以及表决结果是否合法有效发表意见，并不对本次股东大会所审议的议案内容 以及该等议案所表述的相关事实或数据的真实性、准确性或合法性发表意见。 本法律意见书仅供见证本次股东大会相关事项合法性之 ...

Group 1: Company Overview and Activities - Guizhou Langma Information Technology Co., Ltd. participated in the 2025 Guizhou Listed Companies Investor Reception Day and 2024 Annual Performance Briefing on May 12, 2025 [2] - The event was held online via the "Panorama Roadshow" platform, with key personnel including Chairman and General Manager Mr. Wang Wei and other executives present [2] Group 2: Product Development and Revenue - The "39AI Doctor Brain" is continuously being updated and optimized, with a focus on meeting user needs and commercializing with B-end clients such as hospitals and pharmaceutical companies [2] - The "39AI Doctor" product has been launched with features like disease diagnosis and case analysis, generating revenue in some medical institutions and pharmaceutical companies, but not significantly impacting overall company performance yet [2][3] Group 3: Financial Performance and International Revenue - The company's foreign revenue for 2024 was reported at 894,500 yuan, which constitutes a small percentage of total revenue, indicating minimal impact from current tariff policies [3] - Other income in the 2024 annual report includes software sales, rental income, and property management services [3] Group 4: Share Repurchase Plans - The company currently has no plans for share repurchase; any significant matters regarding share repurchase will be announced in accordance with regulations [3]

Core Viewpoint - The company reported a 32.55% year-on-year decrease in R&D expenses for the first quarter of 2025, primarily due to a strategic focus on medical artificial intelligence development, leading to optimization of existing business and personnel [1] Summary by Categories R&D Expenses - The R&D expenses for the first quarter of 2025 amounted to a significant reduction compared to the same period in 2024, with a decrease of 32.55% [1] - The components of R&D expenses include leasing costs, depreciation, custody fees, and labor costs [1] Strategic Focus - The company has concentrated its resources on the development of medical artificial intelligence, which has influenced the reduction in R&D expenses [1] - Optimization of existing business and personnel was a key factor in the decrease of R&D expenses [1]

Group 1 - The core viewpoint of the news is that Langma Information has shown a slight increase in stock price and a positive net profit despite a decline in revenue for the first quarter of 2025 [1] - As of April 25, the closing price of Langma Information is 13.28 yuan, with a market capitalization of 4.488 billion yuan and a price-to-book ratio of 4.13 [1] - The company has experienced a net inflow of 29.2163 million yuan in principal funds on April 25, indicating a generally positive trend in fund flow over the past five days, totaling 3.1732 million yuan [1] Group 2 - Langma Information operates in two main business segments: "Medical Services + Internet Medical Services" and "Telecommunications and Value-Added Telecommunications Services" [1] - The company's primary products include telephone matching services, mobile resale services, medical information services, and software sales [1] - For the first quarter of 2025, Langma Information reported an operating income of 72.9867 million yuan, a year-on-year decrease of 8.15%, while net profit was 6.4954 million yuan, reflecting a year-on-year increase of 2.77% with a gross profit margin of 35.11% [1] Group 3 - The price-to-earnings (P/E) ratio for Langma Information is reported as -8.77 (TTM) and -8.76 (static), with a market capitalization of 4.488 billion yuan [2] - The industry average P/E ratio is 70.36 (TTM) and 68.57 (static), while the industry median is 82.49 (TTM) and 77.54 (static) [2] - The price-to-book ratio for Langma Information is 4.13, compared to the industry average of 5.01 and the industry median of 3.62 [2]

Core Viewpoint - The implementation of the "Pharmaceutical Industry Digital Transformation Implementation Plan (2025-2030)" by seven government departments aims to enhance the digital transformation across the entire pharmaceutical industry chain, focusing on the deep application of artificial intelligence technology and the cultivation of excellent enterprises [1][3]. Group 1: Market Impact - Following the announcement, the pharmaceutical digitalization sector in the A-share market saw a collective rise, with notable increases such as 13.16% for Sichuang Medical [2][1]. - The digital transformation plan is expected to create significant opportunities for the pharmaceutical industry, effectively equipping it with a "digital brain" to enhance efficiency and reduce costs [6][7]. Group 2: Development Goals - The plan outlines two key stages: by 2027, significant progress in digital transformation should be achieved, and by 2030, large-scale pharmaceutical enterprises should have fully realized digital transformation [3][4]. - Specific targets include the development of over 30 digital technology standards and the establishment of more than 100 exemplary application scenarios in the pharmaceutical industry [4][5]. Group 3: Key Tasks - The plan identifies four major tasks: empowering with digital technology, promoting digital transformation, building a digital service system, and enhancing digital regulation [5][6]. Group 4: Market Growth Potential - The digital healthcare market in China is projected to exceed 1.2 trillion yuan by the end of 2024, with a compound annual growth rate of 24.5% [8]. - By 2025, the digital healthcare market is expected to surpass 1.8 trillion yuan, and by 2030, it could reach 2.5 trillion yuan, indicating a significant market opportunity driven by policy, technology, and demand [9]. Group 5: Company Innovations - Companies like Hengrui Medicine and Fosun Pharma are collaborating with AI platforms to enhance the efficiency of innovative drug development [11]. - Other firms, such as WuXi AppTec and Chengdu XianDao, are integrating AI into their research processes to improve precision and efficiency in drug development [10][11].

Core Viewpoint - The company reported a significant decline in revenue and net profit for the year 2024, primarily due to adverse market conditions affecting its core businesses, particularly in internet healthcare and telecommunications services [5][28]. Group 1: Financial Performance - The company achieved operating revenue of 379.07 million yuan, a decrease of 17.52% compared to the previous year [5]. - The net profit attributable to shareholders was -512.10 million yuan, a decline of 761.14% year-on-year [5]. - Excluding goodwill impairment, the net profit attributable to shareholders was 54.38 million yuan, down 29.79% from the previous year [5]. Group 2: Business Segments Internet Healthcare - The company focuses on "Internet + Healthcare," investing heavily in medical AI research and various healthcare services [5]. - The subsidiary 39 Health Network experienced a decline in revenue due to reduced self-operated traffic and changes in advertising policies, leading to a significant drop in its main business income [5]. - The 39 Internet Hospital has over 1 million registered users and has completed over 600,000 medical services across 37 specialties [17]. Telecommunications - The company operates a mobile communication resale business and has obtained licenses from major telecom operators, becoming a virtual operator [29]. - Revenue from the telecommunications segment decreased by 39.67% year-on-year, attributed to regulatory pressures and increased competition [34]. Medical Device and Pharmaceutical Distribution - The smart wearable device segment, operated by a subsidiary, saw a revenue decline of 45.88% due to intense market competition [27]. - The pharmaceutical e-commerce segment reported a revenue of 2.37 billion yuan, a decrease of 4.77%, but net profit increased by 9.99% to 86.90 million yuan [28]. Group 3: Strategic Developments - The company has positioned itself in the medical AI field, developing proprietary AI products aimed at enhancing healthcare services [41]. - The "39AI Doctor" model has been launched and is being promoted to both B-end institutions and C-end users [41].